Clinical Trials Directory

Trials / Completed

CompletedNCT02836990

Prevena™ vs Dermabond in Groin Wound Infections in Vascular Surgery

Prevena™ Incision Management System Versus Dermabond in the Prevention of Groin Wound Infections in Patients Undergoing Vascular Surgery

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
105 (actual)
Sponsor
State University of New York at Buffalo · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study evaluates the clinical efficacy and cost effectiveness of Prevena Incision Management System versus Dermabond in preventing groin wound infections in patients who undergo vascular surgery requiring a groin wound. Half of the patients will receive Dermabond and the other half will receive the Prevena Incision Management System for their groin wounds.

Detailed description

Dermabond and the Prevena Incision Management System are both FDA approved wound care products. Prevena is a negative pressure system which holds the wound together and removes exudate and debris from the site to prevent infection. Dermabond is a surgical glue which holds the wound together to prevents infection. Prevena is more expensive to apply. However, the hypothesis is that the Prevena System will decrease infection rates and therefore, decrease the ultimate cost of the health care needed after surgery.

Conditions

Interventions

TypeNameDescription
DEVICEPrevena Incision Management SystemA negative pressure system which holds incision edges together and removes exudate and debris from site to prevent surgical wound infections
DEVICEDermabondA surgical skin adhesive used to prevent surgical wound infections

Timeline

Start date
2016-07-01
Primary completion
2019-09-01
Completion
2019-09-01
First posted
2016-07-19
Last updated
2020-12-28
Results posted
2020-12-28

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02836990. Inclusion in this directory is not an endorsement.